Abstract
One of the main reasons to use blood rather than bone marrow-derived cells for autotransplants in malignancies is based on the hypothesis that they could be less likely contaminated by residual malignant cells and, consequently, that they might not carry the same risk of relapse as autologous bone marrow cells [1, 3]. This hypothesis originated from the fact that, in lymphohaematopoietic malignancies, the relapse often appears later in peripheral blood than in bone marrow. Some recent data from cytogenetic, genetic, immune and clonogenic assays from patients with malignancies prompt to moderate this assumption. Several variables can indeed influence the risk and the rate of neoplastic contamination. Probably the risk is different according to the type of disease and to its evolutive stage, to prior chemotherapy (in vivo “purging”), to the methods of mobilization and to the number of transplanted cells. Furthermore contribution to relapse of residual tumor cells in autologous grafts is ambiguous and remains to be determined for each individual disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Henon PhR, Buttirini A, Gale RP (1991) Blood-derived haematopoietic cell transplants: blood to blood? Lancet 337: 961–963
Henon PhR, Liang H, Beck-Wirth G, et al. (1992) Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9: 285–291
Kessinger A, Armitage JO (1991) The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77: 211–213
To LB, Roberts MM, Haylock DN, et al. (1992) Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants. Bone Marrow Transplant 9: 277–284
Chronic Myeloid Leukaemia
Barnett MJ, Eaves CJ, Philips GL, et al. (1989) Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant 4: 345–351
Barnett MJ, Eaves CJ, Phillips GL, et al. (1990) Autografting in chronic myeloid leukemia (CML) with cultured marrow: consistent restoration of Philadelphia chromosome (PH’)-negative hematopoiesis in patients selected by prior assessment of their marrow in vitro. Blood 76 [Suppl 1]: 526a (abstract no. 2096)
Brito-Babapulle F, Apperley JF, Rassool F, et al. (1987) Complete remission after autografting for chronic myeloid leukaemia. Leukemia Research, 11: 1115–1117
Buckner CD, Stewart P, Clift RA, et al. (1978) Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exper Hematol 6: 96–109
Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335: 1255–1258
Carella AM, Pollicardo N, Pungolino E, et al. (1993) Mobilization of cytogenetically and molecularly “normal” blood progenitors cells ( BPC) by intensive conventional chemo-therapy for chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia and Lymphoma 9: 477–483
Cashman JD, Otsuka T, Eaves CJ, Humphries RK, Eaves AC (1990) TGF-p has a similarly inhibitory effect on the proliferation of very primitive normal and CML progenitor cells. Exper Hematol 18: 645 (abstract no. 369)
Degliantoni G, Mangoni L, Rizzoli V (1985) In vitro restoration of polyclonal hematopoiesis in chronic myelogenous leukemia after in vitro treatment with 4- hydroperoxycyclophosphamide. Blood 65: 753–757
Goldman JM, Th’ng KH, Park DS, Spiers ASD, Lowenthal RM, Ruutu T (1978) Collection, cryopreservation and subsequent viability of haematopoietic stem cells intended for treatment of chronic granulocytic leukaemia in transformation. Brit J Haematol 40: 185–195
Goldman JM (1991) Autografting for CML: is there a role? In: Champlin RE, Gale RP (eds) New strategies in bone marrow transplantation. Wiley-Liss, New York, pp 155–162
Goldman JM (1991) Use of autologous stem cells in support of intensive treatment of chronic myelogenous leukemia. Chronic Myelogenous Leukemia. In: Deisseroth AB, Arlinghaus RB (eds) Molecular approaches to research and therapy. Marcel Dekker Inc., New York pp 455–467
Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF (1987) Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia. Nature 328: 342–344
Haines ME, Goldman JM, Worsley AM, et al. (1984) Chemotherapy and autografting for patients with chronic granulocytic leukaemia in transformation: probable pro¬longation of life for some patients. Brit J Haematol 58: 711–722
Hughes TP, Brito-Babapulle F, Tollit D, Martiat P, Bowcock S, Th’ng KH, Dowding C, Goldman JM (1991) Induction of Philadelphia-negative hematopoiesis and pro¬longation of chronic phase in patients with chronic myeloid leukemia treated with high dose chemotherapy and transfusion of peripheral blood stem cells. In: Dicke KA, Armitage JO (eds) Autologous bone marrow transplantation. Fifth International Symposium. The University of Nebraska Medical Center, Omaha, Nebraska pp 219–228
Jamieson CHM, McDonald WN, Levy JG (1990) Preferential uptake of benzoporphyr- in derivative by leukemic versus normal cells. Leukemia Research 14: 209–219
Korbling M, Burke P, Braine H, et al. (1981) Successful engraftment of blood-derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exper Hematol 9: 684–690
Lemonier MP, Gorin NC, Laporte JP (1984) Autologous marrow transplantation for patients with chronic myelogenous leukemia in accelerated or blastic phase: report of 14 cases. Exper Hematol 14: 654–658
McGlave PB, Arthur D, Miller WJ, Lasky L, Kersey J (1990) Autologous transplan¬tation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 6: 115–120
Norman JE, Shepherd KM, Dale BM, Sage RE (1981) Collection and cryopreservation of peripheral blood progenitor cells in chronic granulocytic leukaemia - a comparison of treated and untreated patients. Pathology 13: 609–614
Preisler HD, Raza A, Higby D, et al. (1984) Treatment of myeloid crisis of chronic myelogenous leukemia. Cancer Treat Reports 68: 1351–1355
Reiffers J, Gorin NC, Michallet M, Maraninchi D, Herve P (1986) Autografting for chronic granulocytic leukemia in transformation. J Nat Cancer Inst 76: 1307–1311
Robak T, Nolasco I, Hibbin J A, Goldman JM (1985) Antigenic characteristics of circulating CFU-GM in chronic granulocytic leukaemia resemble those of CFU-GM in normal marrow and differ from those in normal blood. Leukemia Research 9: 1023–1029
Thomas R, Robinson WA, Dantas M, et al. (1984) Autologous marrow transplantation for patients with chronic myelogenous leukemia in blast crisis. Amer J Hematol 16: 105–112
Acute Leukaemias
Carella AM, Pollicardo N, Carlier P, et al. (1992) “Normal” peripheral blood stem cells (PBSC) mobilization by myelosuppressive chemotherapy in very high risk acute lymphoblastic leukemia (ALL) with cytogenetic translocations. Leukemia and Lym-phoma 7 [Suppl 2]: 19–21
Henon Ph R, Debecker A, Lepers M, et al. (1988) Collection of circulating stem cells and their use for autograft in adults with acute lymphoblastic leukemia. Nouv Rev Fr Hematol 30: 229–235
Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ (1985) Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haematopoietic reconstitution after high dose melphalan or supralethal radiotherapy. Br J Haematol 61: 739–745
Korbling M, Fliedner TM, Holle R, et al. (1991) Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hematopoietic reconstitution and disease-free survival. Bone Marrow Transplant 7: 343–349
Langlands K, Anderson JS, Parker AC, Anthony RS (1992) Polymerase chain reaction analysis of tumor contamination in peripheral blood stem cell harvests. Int J Cell Cloning 10 [Suppl 1]: 95–97
Leverger G, Schaison G, Reiffers J, et al. (1988) Autologous transplantation with cryopreserved peripheral blood stem cells (PBSC) in 16 leukemic children. Blood 72 [Suppl 1]: 1490 (Abstract)
Reiffers J, Marit G, Rice A, et al. (1991) Peripheral blood stem cell transplantation in patients with acute myeloid leukemia. In: Dicke K, Armitage JO, Dicke-Ewinger MJ (eds) Autologous bone marrow transplantation. Fifth International Symposium. The University of Nebraska Medical Centre, Omaha, Nebraska, pp 823–827
Reiffers J, Korbling M, Labopin M, Henon Ph, Gorin NC (1992) Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. Int J Cell Cloning 10 [Suppl 1]: 111–113
Richman CM, Weiner RS, Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031–1037
Szer J, Juttner CA, To LB, et al. (1992) Post-remission therapy for acute myeloid leukemia with blood-derived stem cell transplantation. Results of a collaborative phase II trial. Intern J Cell Cloning 10 [Suppl 1]: 114–116
Takaue Y, Hoshi Y, Watanabe T, et al. (1992) Collection and autografts of peripheral blood stem cells in children with acute leukemia or non-Hodgkin’s lymphoma. Int J Cell Cloning 10 [Suppl 1]: 152–154
To LB, Haylock DN, Kimber RJ, Juttner CA (1984) High levels of circulating haematopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399–410
To LB, Haylock DN, Dyson PG, Thorp D, Roberts M, Juttner CA (1990) An unusual pattern of haematopoietic reconstitution in patients with acute myeloid leukaemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 6: 109–114
Yokata S, Hansen-Hagge TE, Ludwig WD, et al. (1991) Use of Polymerase Chain Reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77: 331–339
Nori Hodgkin’s Lymphoma
Brice P, Marolleau JP, Dombret H, et al. (1992) Autologous peripheral blood stem cell transplantation after high-dose therapy in patients with advanced lymphoma. Bone Marrow Transplant 9: 337–342
Freedman AS,Takvorian T, Ritz J, Anderson K, Nadler LM (1989) Autologous bone marrow transplantation in low grade non-Hodgkin’s lymphoma. In: Dicke KA, Spitzer G, Jagannath S (eds) Autologous bone marrow transplantation. Fourth International Symposium. The University of Texas, MD Anderson Cancer Centre Houston pp 327–330
Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD (1989) High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74: 1260–1265
Kessinger A, Nademanee A, Forman SJ, et al. (1990) Autologous bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphoma. Hematology/Oncology Clinics of North America 4: 577–587
Kessinger A, Armitage JO (1992) Peripheral stem cell transplantation for patients with non-Hodgkin lymphoma. Int J Cell Cloning 10 [Suppl 1]: 127–128
Körbling M, Dorken B, Ho AD, Pezzuto A, Hunstein W, Fliedner TM (1986) Autologous transplantation of blood-derived hemopoietic stem cells after myeloabla- tive therapy in a patient with Burkitt’s lymphoma. Blood 67: 529–532
Kotasek D, Sage RE, Juttner CA, To LB (1992) Autologous transplantation in non- Hodgkin’s lymphomas using high-dose cyclophosphamide mobilized blood stem cells: the Adelaide experience. Int J Cell Cloning 10 [Suppl 1]: 129–131
Lee MS, Change KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA (1987) Detection of minimal residual cells carrying the small t (14; 18) by DNA sequence amplification. Science 237: 175–178
Rohatiner AZS, Cotter FE, Price CGA, et al. (1989) Ablative therapy supported by autologous bone marrow transplantation ( ABMT) as consolidation of remission in patients with follicular lymphoma. Proceedings of the American Society of Clinical Oncology 8: 266
Sharp JG, Kessinger A, Vaughan WP, et al. (1992) Detection of clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Cloning 10 [Suppl 1]: 92–94
Vose JM, Peterson C, Bierman PJ, et al. (1990) Comparison of high dose therapy and autologous bone marrow transplantation for T-cell and B-cell non Hodgkin’s lymphoma. Blood 76: 424–431
Vose JM, Bierman PJ, Armitage JO (1991) High dose chemotherapy with stem cell rescue for the treatment of follicular low grade non-Hodgkin’s lymphoma. In: Dicke KA, Armitage JO, Dicke-Evinger, Fifth International Symposium. University of Nebraska Medical Center pp 479–485
Hodgkin’s Disease
Haas R, Hohaus S, Egerer G, Ogniben E, Witt B, Hunstein W (1992) Autologous blood stem cell transplantation in relapsed Hodgkin’s disease. Intern J Cell Cloning 10 [Suppll]: 138–140
Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasques WS, Cabanillas F (1987) MIME therapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as a treatment for recurrent Hodgkin’s disease. J Clin Oncol 5: 566–561
Jagannath S, Armitage JO, Dicke KA, et al. (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation. J Clin Oncol 8: 179–185
Jagannath S, Armitage JO, Dicke KA, et al. (1989) Timing of high dose CBV and autologous bone marrow transplantation in the management of relapsed or refractory Hodgkin’s disease. In: Dicke KA, Spitzer G, Jagannath S, Evinger-Hodges MJ (eds) Autologous bone marrow transplantation. Fourth Symposium. University of Texas MD Anderson Cancer Center, Houston Texas, p 275
Kessinger A, Vose J, Bierman PJ, Armitage JO (1992) High dose cyclophosphamide, etoposide and carmustine and peripheral stem cell transplantation for patients with relapsed Hodgkin’s disease and bone marrow abnormalities. Int J Cell Cloning 10 [Suppll]: 135–137
Lasky LC, Hurd DD, Smith JA, Haake R (1989) Peripheral blood stem cell collection and use in Hodgkin’s disease. Comparison with marrow in autologous transplantation. Transfusion 29: 323–327
Myers CE, Chabner BA, De Vita VT, Gralnick HR (1974) Bone marrow involvement in Hodgkin’s disease: pathology and response to MOPP chemotherapy. Blood 44: 197–204
Multiple Myeloma
Barlogie B, Alexanian R, Dicke KA, et al. (1987) High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70: 869–872
Bell A J, Williamson PJ, North J, Watts EJ, Stephens JR (1989) Circulating stem cell autografts in high risk myeloma. Br J Haematol 71: 162–163
Bell AJ, North J, Stevenson FK, Hamblin TJ (1990) Peripheral blood stem cell autografts in myeloma. Bone Marrow Transplant 5 [Suppl 1]: 52–54
Berenson J, Wong R, Kim K, Brown N, Lischtenstein A (1987) Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70: 1550–1553
Eisenmann JC, Henon Ph, Wunder E, et al. (1990) Unequal results of collection of peripheral bloot stem cells in view of autografting in high risk multiple myeloma. Bone Marrow Transplant 5 [Suppl 1]: 56–57
Fermand JP, Levy Y, Gerota J, et al. (1989) Treatment of agressive multiple myeloma by high dose chemotherapy and total body irradiation followed by blood stem cell autologous autografts. Blood 73: 20–23
Fermand JP, Chevret S, Levy Y, et al. (1992) The role of autologous blood stem cells in support of high dose therapy for multiple myeloma. In: Barlogie B (eds) Hematology/ oncology. Clinics of North America. W. B. Saunders, Philadelphia, pp 45–46
Harousseau JL, Milpied N, Garand R, Bourhis JH (1987) High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol 67: 493
Henon Ph, Beck G, Debecker A, Eisenmann JC, Lepers M, Kandel G (1988) Autograft using peripheral blood stem cells collected after high dose melphalan in high risk multiple myeloma. Br J Haematol 70: 254–255
Henon Ph, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E (1991) Autologous blood stem cell transplantation (ABSCT) in high-risk myeloma. In: Dicke KA, Armitage JO, Dicke-Evinger MJ (eds) Autologous bone marrow transplantation. Fifth International Symposium. University of Nebraska Medical Center, Omaha, Nebraska pp 841–849
Henon Ph, Eisenmann JC, Beck-Wirth G, Liang H (1992) A two phase intensive therapeutic approach in high risk myeloma. Follow up. Int J of Cell Cloning 10 [Suppll]: 142–144
Jagannath S, Vesole D, Barlogie B (1991) High dose therapy, autologous stem cells and hematopoietic growth factors for the management of multiple myeloma. In: Armitage J, Antman K (eds) High-dose cancer therapy. Williams and Wilkins, Publishers, Baltimore, Maryland
Jagannath S, Vesole D, Glenn L, Barlogie B (1991) High-dose cyclophosphamide (HDCTX) for blood stem cell mobilization (BSCM) in patients with multiple myeloma. Blood 78 [Suppl 1]: 125 a (Abstract)
Laporte JP, Gorin NC, Dupuy-Montbrun MC, Lopez M, Lemonnier M, Isnard F, Najman A (1988) Failure to collect sufficient amount of peripheral blood stem cells (PBSC) for autografting in patients with endstage multiple myeloma. Bone Marrow Transplant 3 [Suppl 1]: 89
McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1: 822–824
Marit G, Boiron JM, Reiffers J (1990) Autologous blood stem cell transplantation in high-risk myeloma. Bone Marrow Transplant 5 [Suppl 1]: 55
Mauch P, Ferrara J, Hellman S (1989) Stem cell self-renewal considerations in bone marrow transplantation. Bone Marrow Transplant 4: 601–607
Reiffers J, Leverger G, Marit G, et al. (1989) Haematopoietic reconstitution after autologous blood stem cell transplantation. In: Gale RP, Champlin R (eds) Bone marrow transplantation, Current controversies. Liss, New York pp 313–320
Reiffers J, Marit G, Boiron JM (1989) Autologous blood stem cell transplantation in high-risk multiple myeloma. Br J Haematol 72: 296–297
To LB (1990) Assaying the CFU-GM in blood: correlation between cell dose and haematopoietic reconstitution. Bone Marrow Transplant 5 [Suppl 1]: 16–18
Tura S, Cavo M, Baccarani M, Ricci P, Gobbi M (1986) Bone marrow transplantation in multiple myeloma. Scand J Haematol 36: 176–179
Ventura GJ, Barlogie B, Hester JP, et al. (1990) High dose cyclophosphamide, BCNU and VP 16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplant 5: 265–268
Wunder E, Sowala H, Henon Ph (1990) Regulation of progenitor cell stimulation in vitro in health, myeloma and AML. Blood 76 [Suppl 1]:500 a (Abstract)
Solid Tumors
Antman K, Corringham R, de Vries E et al. (1992) Dose intensive therapy in breast cancer. Bone Marrow Transplant 10 [Suppl 1]: 67–73
Emminger W, Höcker P, Emminger-Schmidmeier W, et al. (1992) Autologous blood stem cell transplantation in pediatric cancer patients. The Austrian experience (1986- 1991) Int J Cell Cloning 10 [Suppl 1]: 157–159
Ho JQK, Juttner CA, To LB, et al. (1990) The threshold effect in peripheral blood stem cell autografting - differences between acute myeloid leukaemia and non “stem cell diseases”. J Cell Biochem 14A: 320
Juttner CA, Davy ML J, To LB, et al. (1992) Autologous PBSC transplantation in stage 3 and 4 ovarian cancer. Int J Cell Cloning 10 [Suppl 1]: 145
Kaminer LS, Williams SF, Beschorner J, O’Brian S, Golick J, Bitran JD (1989) High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast cancer. Bone Marrow Transplant 4: 359–362
Kessinger A, Armitage JO, Landmark JD (1986) Use of autologous cryopreserved peripheral stem cells to shorten marrow aplasia after high dose therapy for patients with advanced breast cancer and bone marrow metastases. Proc Am Soc Clin Oncol 5: 245
Ladestein R, Lasset C, Hartmann O, et al. (1992) The Lyon and the EBMT data on megatherapy in neuroblastoma followed by bone marrow rescue. Bone Marrow Transplant 10 [Suppl 2]: 14
Lasky LC, Bostrom B, Smith J, Moss TJ, Ramsay NKC (1989) Clinical collection and use of peripheral blood stem cells in pediatric patients. Transplantation 47: 613–616
Lasky LC, Smith JA, Neglia J, Ramsay NKC, Bostrom B (1992) Treatment of children with neuroblastoma with high dose chemotherapy followed by peripheral blood stem cell hematopoietic rescue. Int J Cell Cloning 10 [Suppl 1]: 155–156
Menichella G, Pierelli L, Foddai ML, et al. (1991) Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 79: 444–450
Moormeir J, Williams S, Kaminer L, Gartner M, Bitran J (1988) High dose trialkylator chemotherapy (TACT II) with autologous stem cell reinfusion in patients with refractory cancer. Clin Res 36:835 A
Nichols CR, Tricot G, Williams SD, et al. (1989) Dose intensive chemotherapy in refractory germ cell cancer. A phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–939
Nürnberger W, Burdach St, Peters C (1992) The chest is the most frequent relapse site after ablative therapy and autologous stem cell rescue for poor prognosis Ewing’ sarcoma. Bone Marrow Transplant 10 [Suppl 1]: 48
Siegert W, Beyer J, Strohscheer I, et al. (1992) High dose carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in poor risk germ cell tumors. Bone Marrow Transplant 10 [Suppl 1]: 26
Stiff PJ, Koester AR, Eagleton LE, Hindman T, Braud E (1987) Autologous stem cell transplantation using peripheral blood stem cells. Transplantation 44: 585–588
Takaue Y, Watanabe T, Abe T, et al. (1992) Experience with peripheral blood stem cell collection for autografts in children with active cancer. Bone Marrow Transplant 10: 241–248
To LB, Haylock DN, Dyson PG (1992) A comparison between 4g/m2 and 7g/m2 cyclophosphamide for peripheral blood stem cell mobilization. Int J Cell Cloning 10 [Suppl 1]: 33
Vaughan WP, Red EC, Kessinger A (1992) High dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue for metastatic breast cancer. In: Dicke KA, Armitage JO (eds) Autologous bone marrow transplantation. Fifth International Symposium. The University of Nebraska Medical Center, Omaha, Nebraska, pp 3432–352
Watanabe T, Takaye Y, Kawano Y, et al. (1989) Peripheral blood stem cell autotrans- plantation in treatment of childhood cancer. Bone Marrow Transplant 4: 261–265
Williams SF, Bitran JD, Kaminer L, et al. (1987) Phase I-II study of bialkylator chemotherapy, high dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 5: 250–265
Williams SF, Myers SE (1992) The University of Chicago experience with high-dose chemotherapy intensification and autologous stem cell rescue for breast cancer. Bone Marrow Transplant 10 [Suppl 2]: 38
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Henon, P.R. (1993). Clinical Aspects of Autologous Blood Stem Cell Transplantations - Review of Indications. In: Wunder, E.W., Henon, P.R. (eds) Peripheral Blood Stem Cell Autografts. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75717-4_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-75717-4_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75719-8
Online ISBN: 978-3-642-75717-4
eBook Packages: Springer Book Archive